Article thumbnail

Evaluation of antibody and T cell responses as well as protective immunity elicited by immunization with different formulations containing the tumor-associated NY-ESO-1 antigen.

By Caroline Junqueira (324145), Ana Tereza Guerrero (324146), Bruno Galvão-Filho (324147), Warrison A. Andrade (324148), Ana Paula C. Salgado (238159), Thiago M. Cunha (276874), Catherine Ropert (324149), Marco Antônio Campos (324150), Marcus L. O. Penido (207618), Lúcia Mendonça-Previato (5652226), José Oswaldo Previato (324151), Gerd Ritter (209869), Fernando Q. Cunha (276880) and Ricardo T. Gazzinelli (164680)


<p>C57BL/6 mice were subjected to three immunization doses on days 0, 14 and 28. (A) Serum levels of NY-ESO-1-specific total IgG, IgG1 and IgG2c; and (B) IFN-γ production by splenocytes stimulated with NY-ESO-1 CD4<sup>+</sup> T and CD8<sup>+</sup> T peptides cells were evaluated by ELISA. (C) Control and immunized mice were challenged with 5×10<sup>4</sup> B16F10 melanoma cell expressing or not NY-ESO-1. The tumor growth was evaluated every 4 days for 40 days after challenge. Asterisks indicate that differences in IFN-γ responses to NY-ESO-1 CD4<sup>+</sup> T and CD8<sup>+</sup> T cell peptide and tumor growth are statistically significant, when comparing mice receiving different vaccine formulations.</p

Topics: Immunology, Cancer, antibody, responses, immunity, elicited, immunization, formulations, containing, tumor-associated, ny-eso-1
Year: 2013
DOI identifier: 10.1371/journal.pone.0036245.g004
OAI identifier:
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.